Showing 581 - 600 results of 99,506 for search '(( 5 non decrease ) OR ( 5 ((wt decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 1.26s Refine Results
  1. 581

    Human preterm infants diagnosed with IUGR have decreased Paneth cell counts compared to preterm non-IUGR control infants. by Camille M. Fung (844334)

    Published 2016
    “…(A) IUGR infants had similar numbers of goblet cells per 100 epithelial cells compared to non-IUGR infants (p = 0.5). …”
  2. 582
  3. 583

    PARP inhibition causes a decrease in Alt-EJ that is enhanced by Ku70 loss. by Sean M. Howard (687174)

    Published 2015
    “…<p>(<b>A</b>) PARPi treatment (Olaparib) causes a specific decrease in Alt-EJ, compared to Distal EJ. …”
  4. 584

    Hippocampus-related memory defects in 9V/null mice evaluated by conditional fear test. by Mei Dai (3105909)

    Published 2016
    “…Freezing events were measured and presented as fold of changes with the tone verse without the tone. 9V/null mice exhibited a significant decrease in response to contextual fear in male and auditory-cued fear in both genders compared to age- and gender-matched WT at 12 months of age. *, p<0.05 (n  =  11–12 mice per group) by two-way ANOVA.…”
  5. 585

    Decreased HIF levels associated with hyperoxic cell state. by Julie M. Koeman (108185)

    Published 2008
    “…<p>(A) Normalized densitometry of HIF-1α protein levels (•),HIF-1β protein levels (▴), and HIF-1 DNA-binding activity (⧫) as presented in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000176#pgen-1000176-g005" target="_blank">Figure 5B</a> of the Jiang et al. article. …”
  6. 586
  7. 587
  8. 588

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  9. 589

    Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…<b>a. RT-qPCR analysis:</b> relative TMPRSS2-ERG fusion variants III and IV mRNA levels were analysed and compared to non-treated cells. …”
  10. 590

    MMR mutants show decreased mating-type silencing. by Qian Liu (135614)

    Published 2020
    “…MMR deletion strains (<i>pms1Δ</i>, <i>mlh1Δ</i>, and <i>msh2Δ</i>) displayed white with sectors colonies as compared to WT, indicating a loss of gene silencing at the telomere <i>ADE2</i> reporter. …”
  11. 591
  12. 592
  13. 593
  14. 594
  15. 595
  16. 596
  17. 597
  18. 598
  19. 599
  20. 600